Skip to main content

Advertisement

SpringerLink
Log in

Ipilimumab treatment associated with myasthenic crises and unfavorable disease course

  • Brief Communication
  • Published:
Neurological Sciences Aims and scope Submit manuscript

Abstract

Ipilimumab, a monoclonal antibody targeting the cytotoxic T lymphocyte antigen-4 is a treatment option for metastatic melanoma. This receptor serves as an inhibitor receptor on T lymphocytes and blockage of these results predisposition to autoimmune diseases. The patients with autoimmune disorders were excluded in clinical trials and there is no sufficient data of the treatment on these patients who already have an autoimmune disorder. Here, we report a case of myasthenia gravis who was treated with ipilimumab and we presented the long-term prognosis of the patient after treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Bertrand A, Kostine M, Barnetche T, Truchetet ME, Schaeverbeke T (2015) Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med 13:211. https://doi.org/10.1186/s12916-015-0455-8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F, Guminski A, Puzanov I, Lawrence DP, Buchbinder EI, Mudigonda T, Spencer K, Bender C, Lee J, Kaufman HL, Menzies AM, Hassel JC, Mehnert JM, Sosman JA, Long GV, Clark JI (2016) Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol 2(2):234–240. https://doi.org/10.1001/jamaoncol.2015.4368

    Article  PubMed  Google Scholar 

  3. Kolb NA, Trevino CR, Waheed W, Sobhani F, Landry KK, Thomas AA, Hehir M (2018) Neuromuscular complications of immune checkpoint inhibitor therapy. Muscle Nerve. https://doi.org/10.1002/mus.26070

    Article  Google Scholar 

  4. Makarious D, Horwood K, Coward JIG (2017) Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors. Eur J Cancer 82:128–136. https://doi.org/10.1016/j.ejca.2017.05.041

    Article  CAS  PubMed  Google Scholar 

  5. Perez-De-Lis M, Retamozo S, Flores-Chavez A, Kostov B, Perez-Alvarez R, Brito-Zeron P, Ramos-Casals M (2017) Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS registry). Expert Opin Drug Saf 16(11):1255–1271. https://doi.org/10.1080/14740338.2017.1372421

    Article  CAS  PubMed  Google Scholar 

  6. Wang HB, Shi FD, Li H, Chambers BJ, Link H, Ljunggren HG (2001) Anti-CTLA-4 antibody treatment triggers determinant spreading and enhances murine myasthenia gravis. J Immunol 166(10):6430–6436

    Article  CAS  PubMed  Google Scholar 

  7. Zhu J, Li Y (2016) Myasthenia gravis exacerbation associated with pembrolizumab. Muscle Nerve 54(3):506–507. https://doi.org/10.1002/mus.25055

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Baskent University Faculty of Medicine, Mareşal Fevzi Çakmak Cad 10.sok No: 45 Bahçelievler, Ankara, Turkey

    Eda Derle & Sibel Benli

Authors
  1. Eda Derle
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sibel Benli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eda Derle.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Derle, E., Benli, S. Ipilimumab treatment associated with myasthenic crises and unfavorable disease course. Neurol Sci 39, 1773–1774 (2018). https://doi.org/10.1007/s10072-018-3471-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-018-3471-6

Keywords

Search

Navigation